AMPH
Income statement / Annual
Last year (2024), Amphastar Pharmaceuticals, Inc.'s total revenue was $712.81 M,
an increase of 10.62% from the previous year.
In 2024, Amphastar Pharmaceuticals, Inc.'s net income was $159.52 M.
See Amphastar Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$712.81 M |
$644.40 M |
$498.99 M |
$437.77 M |
$349.85 M |
$322.36 M |
$294.67 M |
$240.18 M |
$255.17 M |
$251.52 M |
| Cost of Revenue |
$338.96 M
|
$293.27 M
|
$250.13 M
|
$238.03 M
|
$206.51 M
|
$190.43 M
|
$187.68 M
|
$149.38 M
|
$150.98 M
|
$174.17 M
|
| Gross Profit |
$373.86 M
|
$351.12 M
|
$248.86 M
|
$199.74 M
|
$143.34 M
|
$131.92 M
|
$106.99 M
|
$90.80 M
|
$104.19 M
|
$77.35 M
|
| Gross Profit Ratio |
0.52
|
0.55
|
0.5
|
0.46
|
0.41
|
0.41
|
0.36
|
0.38
|
0.41
|
0.31
|
| Research and Development Expenses |
$73.91 M
|
$73.74 M
|
$74.77 M
|
$60.93 M
|
$67.23 M
|
$68.85 M
|
$57.56 M
|
$43.42 M
|
$41.20 M
|
$37.07 M
|
| General & Administrative Expenses |
$56.72 M
|
$51.54 M
|
$45.06 M
|
$51.43 M
|
$50.38 M
|
$50.28 M
|
$49.89 M
|
$44.46 M
|
$41.83 M
|
$41.50 M
|
| Selling & Marketing Expenses |
$37.80 M
|
$28.85 M
|
$21.53 M
|
$17.49 M
|
$14.78 M
|
$12.83 M
|
$8.16 M
|
$6.46 M
|
$5.47 M
|
$5.47 M
|
| Selling, General & Administrative Expenses |
$94.52 M
|
$80.39 M
|
$66.59 M
|
$68.92 M
|
$65.16 M
|
$63.11 M
|
$58.04 M
|
$50.92 M
|
$47.30 M
|
$46.97 M
|
| Other Expenses |
$0.00
|
$0.00
|
$8.54 M
|
$14.25 M
|
-$6.32 M
|
$60.27 M
|
-$1.30 M
|
$2.52 M
|
-$746,000.00
|
-$2.79 M
|
| Operating Expenses |
$168.44 M
|
$154.13 M
|
$141.36 M
|
$129.85 M
|
$132.39 M
|
$131.96 M
|
$115.61 M
|
$94.33 M
|
$88.50 M
|
$84.04 M
|
| Cost And Expenses |
$507.40 M
|
$447.41 M
|
$391.49 M
|
$367.88 M
|
$338.89 M
|
$322.40 M
|
$303.29 M
|
$243.71 M
|
$239.47 M
|
$258.21 M
|
| Interest Income |
$10.61 M
|
$5.46 M
|
$1.32 M
|
$601,000.00
|
$642,000.00
|
$997,000.00
|
$456,000.00
|
$425,000.00
|
$270,000.00
|
$315,000.00
|
| Interest Expense |
$30.34 M
|
$27.16 M
|
$1.85 M
|
$885,000.00
|
$374,000.00
|
$119,000.00
|
$243,000.00
|
$826,000.00
|
$1.02 M
|
$987,000.00
|
| Depreciation & Amortization |
$57.21 M
|
$41.78 M
|
$28.74 M
|
$26.75 M
|
$25.18 M
|
$21.12 M
|
$16.52 M
|
$15.81 M
|
$14.56 M
|
$13.25 M
|
| EBITDA |
$277.31 M |
$240.29 M |
$107.50 M |
$111.78 M |
$30.19 M |
$81.47 M |
$6.83 M |
$11.90 M |
$30.53 M |
$3.88 M |
| EBITDA Ratio |
0.39
|
0.37
|
0.22
|
0.16
|
0.03
|
-0
|
-0.03
|
-0.03
|
0.06
|
0.02
|
| Operating Income Ratio |
0.29
|
0.31
|
0.16
|
0.1
|
-0.04
|
-0
|
-0.03
|
-0
|
0.06
|
-0.03
|
| Total Other Income/Expenses Net |
-$15.66 M
|
-$25.63 M
|
$8.54 M
|
$14.25 M
|
-$6.32 M
|
$60.27 M
|
-$1.30 M
|
$2.52 M
|
-$746,000.00
|
-$3.47 M
|
| Income Before Tax |
$189.76 M
|
$171.36 M
|
$116.04 M
|
$84.14 M
|
$4.64 M
|
$60.23 M
|
-$9.93 M
|
$1.62 M
|
$14.95 M
|
-$10.36 M
|
| Income Before Tax Ratio |
0.27
|
0.27
|
0.23
|
0.19
|
0.01
|
0.19
|
-0.03
|
0.01
|
0.06
|
-0.04
|
| Income Tax Expense |
$29.67 M
|
$31.83 M
|
$23.48 M
|
$20.63 M
|
$3.54 M
|
$13.72 M
|
-$3.27 M
|
-$2.89 M
|
$4.41 M
|
-$7.58 M
|
| Net Income |
$159.52 M
|
$137.55 M
|
$91.39 M
|
$62.12 M
|
$1.10 M
|
$48.94 M
|
-$5.74 M
|
$4.51 M
|
$10.53 M
|
-$2.79 M
|
| Net Income Ratio |
0.22
|
0.21
|
0.18
|
0.14
|
0
|
0.15
|
-0.02
|
0.02
|
0.04
|
-0.01
|
| EPS |
3.29 |
2.85 |
1.88 |
1.3 |
0.0233 |
1.04 |
-0.12 |
0.1 |
0.23 |
-0.062 |
| EPS Diluted |
3.06 |
2.6 |
1.74 |
1.25 |
0.0223 |
0.98 |
-0.12 |
0.09 |
0.22 |
-0.062 |
| Weighted Average Shares Out |
$48.43 M
|
$48.27 M
|
$48.55 M
|
$47.78 M
|
$47.04 M
|
$46.98 M
|
$46.40 M
|
$46.11 M
|
$45.38 M
|
$44.96 M
|
| Weighted Average Shares Out Diluted |
$52.06 M
|
$53.00 M
|
$52.43 M
|
$49.78 M
|
$49.12 M
|
$49.91 M
|
$46.40 M
|
$48.37 M
|
$47.50 M
|
$44.96 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
